Loading
NASDAQHealthcareBiotechnology
Latest quote
$32.01
+$1.42 · +4.64%
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Latest quote
$32.01
+$1.42 · +4.64%
After-hours
$31.56
−$0.45 · -1.41%
Oct 8, 7:33 PM ET
Regular session · ET · Market data may be delayed.
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Day range
Current $32.01
52-week range
Current $32.01
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
52
Mixed
Risk
43
Elevated Risk
Momentum
81
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Day range
Current $32.01
52-week range
Current $32.01
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cost of goods sold | 139.61M USD | 152.35M USD | — |
| Gross profit | −139.61M USD | −152.35M USD | — |
| Research and development | 139.61M USD | 152.35M USD | 97.59M USD |
| Selling, general, and administrative | 39.39M USD | 28.76M USD | 20.87M USD |
| Operating expenses | 39.39M USD | 28.76M USD | 118.46M USD |
| Interest income | 12.94M USD | 17.38M USD | 12.31M USD |
| Depreciation and amortization | 2.42M USD | 2.4M USD | 2.38M USD |
| Operating income | −179.01M USD | −181.1M USD | −118.46M USD |
| Net income | −166.09M USD | −163.71M USD | −106.15M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI46.5M0.00%2.3T USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI27.48M0.27%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM26.84M0.03%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF13.07M0.01%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO6.68M0.05%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO5.61M0.03%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA4.94M0.02%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC3.22M0.24%1.33B USD0.60%$182.79-0.31%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
